Shanghai Hengrun Dasheng Biotechnology

Shanghai Hengrun Dasheng Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of advanced cell therapies for cancer treatment. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T), T-cell Receptor (TCR-T), and Natural Killer (NK) cell technologies to address unmet needs in hematological malignancies and solid tumors. Their lead candidate, HR001, is a CD19-targeted CAR-T therapy currently in pivotal clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma. Hengrun Dasheng maintains integrated capabilities spanning discovery, clinical development, and GMP-compliant manufacturing. Based in Shanghai, the company aims to provide accessible and effective precision medicine to patients globally.